secwatch / observer
8-K filed February 6, 2024, 6:59 PM ET ticker APVO CIK 0001671584
other material confidence high sentiment neutral materiality 0.75

Aptevo stockholders approve reverse stock split (1:15-44) and warrant issuance >19.99%

Aptevo Therapeutics Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Aptevo Therapeutics Inc. shareholders approved To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a ratio in the range of 1-for-15 to 1-for-44, with such ratio to be determined in the discretion of the Board and with such reverse stock split at the 2024-02-05 meeting.

Proposal
reverse split
Outcome
passed
Meeting
2024-02-05
Exact text from the filing
Proposal 1: To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company common stock at a ratio in the range of 1-for-15 to 1-for-44, with such ratio to be determined in the discretion of the Board and with such reverse stock split to be effected at such time and date, if at all, as determined by the Board in its sole discretion. FOR AGAINST ABSTAIN BROKER NON-VOTES 7,159,500 2,477,700 27,721 0
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Aptevo Therapeutics Inc. shareholders approved To approve, in accordance with Nasdaq Listing Rule 563(d), the issuance of more than 19.99% of the Company’s outstanding common stock, par value $0.001 per share, issuable upon the exercise of New Series A-2 Warrants and New Series B-2 Warrants with the right for such potential exercise to occur imm at the 2024-02-05 meeting.

Outcome
passed
Meeting
2024-02-05
Exact text from the filing
Proposal 2: To a pprove, in accordance with Nasdaq Listing Rule 563(d), the issuance of more than 19.99% of the Company’s outstanding common stock, par value $0.001 per share, issuable upon the exercise of New Series A-2 Warrants and New Series B-2 Warrants with the right for such potential exercise to occur immediately following the date upon which stockholders approve this proposal. FOR AGAINST ABSTAIN BROKER NON-VOTES 3,977,073 1,495,805 26,255 4,165,788
View on SEC.gov

Browse all shareholder votes →

Aptevo Therapeutics Inc. filing history →

Source: SEC EDGAR
accession 0000950170-24-011766
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.